| abstract |
The invention relates to novel therapeutic compounds for use against Huntington's disease. More specifically, the invention relates to an isolated peptide which is less than 100 amino acids in size and which comprises: a first sequence having at least 80% identity with sequence AASSG (SEQ ID No 1), or a second sequence having at least 80% identity with sequence XAGXDXXTEXPXS (SEQ ID No 2), in which X denotes any amino acid. The present invention also relates to the use of an isolated peptide, which is less than 200 amino acids in size and which comprises the above-mentioned sequence(s), as a drug. |